Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study
Author:
Funder
AbbVie
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Link
https://link.springer.com/content/pdf/10.1007/s10067-021-05893-3.pdf
Reference38 articles.
1. Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957–970. https://doi.org/10.1056/NEJMra1505557
2. Tucker LJ, Coates LC, Helliwell PS (2019) Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther 6(1):23–32. https://doi.org/10.1007/s40744-018-0132-4
3. Lubrano E, Scriffignano S, Perrotta FM (2019) TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. Expert Rev Clin Immunol 15(12):1303–1312. https://doi.org/10.1080/1744666x.2020.1685382
4. Pukšić S, Bolton-King P, Sexton J, Michelsen B, Kvien TK, Berner Hammer H (2018) DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs. RMD Open 4(2):e000765. https://doi.org/10.1136/rmdopen-2018-000765
5. Bagel J, Schwartzman S (2018) Enthesitis and dactylitis in psoriatic disease: a guide for dermatologists. Am J Clin Dermatol 19(6):839–852. https://doi.org/10.1007/s40257-018-0377-2
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparing DAPSA, DAPSA28, and DAS28‐CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries;Arthritis Care & Research;2024-08-19
2. Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors;Journal of Clinical Medicine;2023-07-31
3. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study;Arthritis Research & Therapy;2023-06-23
4. Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry;Rheumatology and Therapy;2022-11-04
5. The effect of risankizumab on achieving minimal clinically important differences in patient‐reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2;Journal of the European Academy of Dermatology and Venereology;2022-10-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3